APP and Cognitive impairment: TMAO levels are significantly elevated in AD patients, and studies demonstrate that plasma TMAO concentrations greater than five μM correlate with faster hippocampal atrophy, cognitive deficits, and microglial activation in humans and in APP/PS1 mouse models [60, 79].